NCT03075527 - A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 10, 2017

Primary Completion Date

June 7, 2019

Study Completion Date

December 16, 2024

Conditions

Mesothelioma

Interventions

DRUG

Tremelimumab

Tremelimumab blocks a receptor on immune cells that normally suppresses immune attack.

DRUG

Durvalumab

Durvalumab is a drug that blocks a protein often produced by cancer cells or surrounding cells to suppress immune cells from attacking cancer cells.

Trial Locations (1)

Dana Farber Cancer Institute, Boston